ORBIMED ADVISORS LLC
Q1 2023 13F-HR Holdings
Net value change ($000)
-133,412
(-2.6%)
New positions
18
Sold out positions
16
Turnover %
17.8%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ELVN | 197,017 | NEW |
| BIIB | 68,904 | 96.4% |
| Theseus Pharmaceuticals, Inc. | 67,211 | 78.3% |
| LLY | 63,876 | NEW |
| BAX | 63,355 | NEW |
| APLS | 60,037 | NEW |
| R1 RCM Inc. /DE | 26,250 | NEW |
| AMLX | 23,868 | NEW |
| REGN | 19,720 | NEW |
| AMGN | 18,542 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Seagen Inc. | -117,434 | -100.0% |
| PFE | -71,408 | -100.0% |
| UNH | -71,298 | -35.3% |
| 89bio, Inc. | -46,577 | -100.0% |
| ACRS | -43,445 | -100.0% |
| CMPX | -39,358 | -35.0% |
| PCVX | -34,187 | -55.6% |
| VRNA | -33,919 | -28.4% |
| EWTX | -33,068 | -25.4% |
| NBIX | -32,642 | -39.7% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
44,859
(0.9% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|